TORONTO– Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial. Tirzepatide provided a 47% greater relative weight loss compared to Wegovy® (semaglutide). On average, tirzepatide led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. At 72 weeks, tirzepatide was superior to Wegovy on both the primary endpoint and all five …